• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Should patents for antiretrovirals be waived in the developing world? Annual Varsity Medical Debate--London, 21 January 2011.抗逆转录病毒药物在发展中国家应否豁免专利?2011年1月21日于伦敦举行的年度大学医学辩论会
Philos Ethics Humanit Med. 2011 Jul 8;6:13. doi: 10.1186/1747-5341-6-13.
2
Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments.评估强制许可在发展中国家的效用:泰国与巴西在获取艾滋病治疗方面经验的比较研究
Dev World Bioeth. 2017 Aug;17(2):90-99. doi: 10.1111/dewb.12124. Epub 2016 Oct 4.
3
Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?面向服务不足市场的可负担抗逆转录病毒药物:在充满挑战的情况下如何扩大公平可及性?
Curr HIV Res. 2006 Jan;4(1):3-20. doi: 10.2174/157016206775197592.
4
Should trainee doctors use the developing world to gain clinical experience? The annual Varsity Medical Debate - London, Friday 20th January, 2012.实习医生应该利用发展中世界来积累临床经验吗?2012年1月20日星期五于伦敦举行的年度大学医学辩论会。
Philos Ethics Humanit Med. 2013 Feb 21;8:1. doi: 10.1186/1747-5341-8-1.
5
Driving a decade of change: HIV/AIDS, patents and access to medicines for all.推动十年变革:艾滋病毒/艾滋病、专利与全民获得药物。
J Int AIDS Soc. 2011 Mar 27;14:15. doi: 10.1186/1758-2652-14-15.
6
University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.大学对人乳头瘤病毒疫苗的贡献及对发展中国家疫苗可及性的影响:在大学技术转让政策中解决材料和技术诀窍问题
Am J Law Med. 2009;35(2-3):253-79. doi: 10.1177/009885880903500202.
7
The 2014 Varsity Medical Ethics Debate: should we allow genetic information to be patented?2014年大学医学伦理辩论:我们应该允许基因信息被专利化吗?
Philos Ethics Humanit Med. 2015 May 20;10:8. doi: 10.1186/s13010-015-0028-7.
8
[HIV antiretroviral agents: new threats to accessibility in developing countries].[艾滋病毒抗逆转录病毒药物:对发展中国家可及性的新威胁]
Rev Med Suisse. 2005 Dec 14;1(45):2956.
9
Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.获得通用抗逆转录病毒药物:不平等、知识产权法与国际贸易协定。
Cad Saude Publica. 2007;23 Suppl 1:S85-96. doi: 10.1590/s0102-311x2007001300010.
10
Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.维护健康权高于专利权:泰国和巴西强制许可使用过程的比较研究
Dev World Bioeth. 2014 Aug;14(2):83-91. doi: 10.1111/dewb.12050. Epub 2014 Apr 21.

本文引用的文献

1
Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care.在马拉维蒂约洛,通过任务转移和艾滋病毒/艾滋病护理的权力下放,为所有人提供抗逆转录病毒治疗。
Trop Med Int Health. 2010 Dec;15(12):1413-20. doi: 10.1111/j.1365-3156.2010.02649.x. Epub 2010 Oct 19.
2
Should the NHS be privatized? Annual varsity medical debate - London, 22 January 2010.国民保健制度应该私有化吗?年度大学医学辩论会——2010年1月22日于伦敦
Philos Ethics Humanit Med. 2010 May 11;5:7. doi: 10.1186/1747-5341-5-7.
3
Technology Development Through Pooling ARV Drug Patents: A Vision from China.通过整合抗逆转录病毒药物专利推动技术发展:来自中国的愿景。
Open AIDS J. 2010 Jan 19;4:54-9. doi: 10.2174/1874613601004020054.
4
The Health Impact Fund: boosting pharmaceutical innovation without obstructing free access.健康影响基金:在不妨碍药物免费获取的情况下促进制药创新。
Camb Q Healthc Ethics. 2009 Winter;18(1):78-86. doi: 10.1017/S0963180108090129.
5
The cost of antiretroviral therapy in Haiti.海地的抗逆转录病毒疗法成本。
Cost Eff Resour Alloc. 2008 Feb 14;6:3. doi: 10.1186/1478-7547-6-3.
6
Estimating the cost of new drug development: is it really 802 million dollars?估算新药研发成本:真的是8.02亿美元吗?
Health Aff (Millwood). 2006 Mar-Apr;25(2):420-8. doi: 10.1377/hlthaff.25.2.420.
7
First, do no harm: a call for emphasizing adherence and HIV prevention interventions in active antiretroviral therapy programs in the developing world.
AIDS. 2002 Mar 8;16(4):676-8. doi: 10.1097/00002030-200203080-00025.
8
Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?抗逆转录病毒药物的专利是否限制了非洲地区获得艾滋病治疗的机会?
JAMA. 2001 Oct 17;286(15):1886-92. doi: 10.1001/jama.286.15.1886.
9
Experts clash over likely impact of cheap AIDS drugs in Africa.专家们就廉价艾滋病药物在非洲可能产生的影响展开了激烈争论。
Nature. 2001 Apr 5;410(6829):615-6. doi: 10.1038/35070733.

抗逆转录病毒药物在发展中国家应否豁免专利?2011年1月21日于伦敦举行的年度大学医学辩论会

Should patents for antiretrovirals be waived in the developing world? Annual Varsity Medical Debate--London, 21 January 2011.

作者信息

Corrick Fenella, Watson Robert, Budhdeo Sanjay

机构信息

Oriel College, University of Oxford, Oriel Square, Oxford, OX1 4EW, UK.

出版信息

Philos Ethics Humanit Med. 2011 Jul 8;6:13. doi: 10.1186/1747-5341-6-13.

DOI:10.1186/1747-5341-6-13
PMID:21740573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3160882/
Abstract

The 2011 Varsity Medical Debate, between Oxford and Cambridge Universities, brought students and faculty together to discuss the waiving of patents for antiretroviral therapies in the developing world. With an estimated 29.5 million infected by Human Immunodeficiency Virus (HIV) in low- and middle-income countries and only 5.3 million of those being treated, the effective and equitable distribution of anti-retroviral therapy (ART) is an issue of great importance. The debate centred around three areas of contention. Firstly, there was disagreement about whether patents were the real barrier to the access of anti-retroviral therapy in the developing world. Secondly, there were differing views on the effectiveness of a patent pool. Thirdly, concerns were raised over the impact of waiving patents on research to produce new and better anti retro-viral drugs.

摘要

2011年牛津大学与剑桥大学之间的校际医学辩论会,让学生和教师齐聚一堂,共同探讨在发展中国家放弃抗逆转录病毒疗法专利的问题。据估计,低收入和中等收入国家有2950万人感染了人类免疫缺陷病毒(HIV),但其中只有530万人接受治疗,因此抗逆转录病毒疗法(ART)的有效且公平分配是一个极其重要的问题。辩论集中在三个有争议的领域。首先,对于专利是否是发展中国家获取抗逆转录病毒疗法的真正障碍存在分歧。其次,关于专利池的有效性存在不同观点。第三,有人担心放弃专利会对研发新的更好的抗逆转录病毒药物的研究产生影响。